VIPS-MRI

Novel promising MRI sequences have been developed that are possibly sufficiently sensitive to allow monitoring of structural abnormalities(12). In addition, MRI sequences have been developed that possible allow non-invasive monitoring of perfusion and ventilation(13). Finally, MRI sequences have been developed to detect lung inflammation, which could allow the monitoring of lung inflammation without the need for PET-CT or PET-MRI(14).

However, before these novel MRI sequences can be utilized routinely, to improve our monitoring options for CFLD on a wider scale, they have to be integrated into a patient-friendly time-efficient protocol that can be standardized across centers for the major MRI vendors (GE, Philips, Siemens). In addition, some further validation of these novel sequences is needed.

In 2014 we formed the ventilation, inflammation, perfusion and structure (VIPS-MRI) consortium with the ambition to jointly develop a VIPS-MRI platform that could be used across MRI vendors. The VIPS-MRI consortium includes the following centers: Erasmus MC (EMC), Rotterdam, Netherlands; Medizinische Hochschule Hannover (MHH), Hannover, Germany; Royal Hallamshire Hospital Sheffield (RHHS), Sheffield, UK and Princess Margaret Hospital (PMH), Perth, Australia.

Objective of the study

The final goal of this validation plan is to develop an MRI platform that can provide information about ventilation, inflammation, perfusion and structure (VIPS-MRI) in a single MRI examination of 30 minutes for safe and efficient monitoring of CFLD.

we hypothesize that VIPS-MRI can be developed into a patient friendly time efficient MRI to measure ventilation inflammation perfusion and structure without the use of medical gases or contrast

one visit

VIPS-MRI ( max 2x) and for healthy controls flow volume curve